Biomarkers for colorectal cancer
AssigneesGeorge Mason Intellectual Properties, Inc., Istituto Superiore di Sanita
InventorsEmanuel Petricoin, Weidong Zhou, Serena Camerini, Maria Letizia Polci, Lance Liotta
Life of this patent
Estimating the term…
Abstract
Low molecular weight (LMW) peptides have been discovered that are indicative of colorectal cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting colorectal cancer and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting colorectal cancer during its early stages.
Claims20
A method for detecting colorectal cancer in a patient, comprising:
- (i) obtaining a biological sample from said patient;
- and
- (ii) evaluating said sample or a fraction of said sample for the presence of at least one biomarker selected from the group of peptides having the sequences of SEQ ID NOs:
- 176-388,
- wherein the presence of said at least one biomarker is indicative of colorectal cancer.
A method for monitoring the progression of colorectal cancer in a patient, comprising:
- (i) obtaining a biological sample from said patient;
- (ii) evaluating said sample or a fraction of said sample for the presence of at least one biomarker selected from the group of peptides having the sequences of SEQ ID NOs:
- 176-388, wherein the presence of said at least one biomarker is indicative of colorectal cancer;
- and optionally
- (iii) repeating steps (i) and (ii).
An antibody specific for a peptide selected from the group of peptides having the sequences of SEQ ID NOs:
- 176-388.
Dependencies are inferred from the claim text.